Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers with ...

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.

The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and ...

Researchers develop targeted polymersomes loaded with methotrexate for the treatment of gestational choriocarcinoma, ...

JPMorgan raised the firm’s price target on Auna (AUNA) to $13.50 from $13 and keeps an Overweight rating on the shares. The company’s main ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas worldwide.

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...

The American Cancer Society is calling on the Trump administration to restore access to comprehensive scientific data.